Incyte Announces Major Collaboration And License Agreement For Two Hematology-Onco...
Incyte Corporation announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an o...
PharmaceuticalOnline,
Tue Dec 01 01:38:24 PST 2009
• Found on Yahoo! News
SuperGen Data Presentations at American Society of Hematology (ASH) Annual Meeting
DUBLIN, Calif.----SuperGen, Inc. , a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced the acceptance of two abstracts for poster ...
Business Wire via Yahoo! Finance,
Tue Dec 01 03:00:00 PST 2009
• Found on Yahoo! News
Topix.net
360,000 news channels, from Autos to your ZIP code.
• Found on Topix News
VELCADE® (Bortezomib) for Injection to be Featured in Plenary Session at American ...
CAMBRIDGE, Mass.----Millennium: The Takeda Oncology Company today announced nearly 200 abstracts have been accepted for presentation at the annual meeting of the American Society of Hematol...
Business Wire via Yahoo! Finance,
Mon Nov 30 12:19:00 PST 2009
• Found on Yahoo! News
Micromet to Present Updates on Clinical Trials with Blinatumomab at Annual Meeting...
Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present...
PR Newswire via Yahoo! Finance,
Mon Nov 30 04:00:00 PST 2009
• Found on Yahoo! News
Calistoga Pharmaceuticals Announces Two Oral Presentations on CAL-101 at 51st Amer...
SEATTLE----Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective phosphatidylinositol 3 kinase inhibitors for the treatment of cancer and inflammatory diseases...
Business Wire via Yahoo! Finance,
Tue Dec 01 05:03:00 PST 2009
• Found on Yahoo! News
Acceleron Pharma to Present Data on ACE-011 and ACE-536 at the 51st Annual Meeting...
CAMBRIDGE, Mass.----Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, ...
Business Wire via Yahoo! Finance,
Tue Dec 01 05:15:00 PST 2009
• Found on Yahoo! News
Sunesis to Host Conference Call on Tuesday, December 8th to Discuss New Phase 2 Vo...
SOUTH SAN FRANCISCO, CA--(Marketwire - December 1, 2009) - Sunesis Pharmaceuticals, Inc. ( NASDAQ : SNSS ) today announced that the company will host a conference call on Tuesday, December ...
Marketwire,
Tue Dec 01 04:49:18 PST 2009
• Found on Yahoo! News
Amgen to present updated data on Nplate at the 2009 ASH meeting
Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® (romiplostim) in adult chronic immune (idiopathic) thrombocytopenic purpura (ITP). Add...
News-Medical-Net,
Tue Dec 01 01:30:24 PST 2009
• Found on Yahoo! News
ChemGenex Pharmaceuticals to present updated clinical data from its clinical trial...
ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro
News-Medical-Net,
Mon Nov 30 23:15:37 PST 2009
• Found on Yahoo! News
Eleven Rigel Product Candidate Presentations at 2009 ASH Meeting
Rigel Pharmaceuticals, Inc. today announced that eleven presentations on preclinical studies of the company's product candidates will be given at the upcoming American Society of Hematology...
PR Newswire via Yahoo! Finance,
Tue Dec 01 04:30:00 PST 2009
• Found on Yahoo! News
Spectrum Pharmaceuticals Announces ZEVALIN® Data Presentations at the 51st Annual ...
IRVINE, Calif.----Spectrum Pharmaceuticals, Inc. , a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN will be presented...
Business Wire via Yahoo! Finance,
Tue Dec 01 04:00:00 PST 2009
• Found on Yahoo! News
Hana Biosciences to Present Data From Pivotal rALLy Clinical Trial of Marqibo(R) i...
SOUTH SAN FRANCISCO, Calif. -- Hana Biosciences , a biopharmaceutical company focused on strengthening the foundation of cancer care, today announced that top-line data from its pivotal Pha...
GlobeNewswire via Yahoo! Finance,
Tue Dec 01 04:00:00 PST 2009
• Found on Yahoo! News
City Paper Blogs
Sherri Sosslau is in the process of making 40 colorful yarn wigs for kids who are residents of the Hematology Department at Children's National Medical Center . She has 12 so far, and could...
Washington City Paper,
Mon Nov 30 15:54:26 PST 2009
• Found on Yahoo! News
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at ...
SOUTH SAN FRANCISCO, CA--(Marketwire - November 30, 2009) - Cytokinetics, Incorporated ( NASDAQ : CYTK ) announced today that an abstract summarizing clinical trial data regarding SB-743921...
Marketwire,
Mon Nov 30 13:04:15 PST 2009
• Found on Yahoo! News
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to Be Presented at ...
SOUTH SAN FRANCISCO, CA--(Marketwire - 11/30/09) - Cytokinetics, Incorporated (NASDAQ: CYTK - News ) announced today that an abstract summarizing clinical trial data regarding SB-743921 is ...
Marketwire via Yahoo! Finance,
Mon Nov 30 13:00:00 PST 2009
• Found on Yahoo! News
Amgen Highlights Data to be Presented at ASH
Amgen Inc. today announced that it will present updated long-term safety and efficacy data for Nplate® in adult chronic immune thrombocytopenic purpura . Additionally, Amgen will present th...
PR Newswire via Yahoo! Finance,
Mon Nov 30 05:51:00 PST 2009
• Found on Yahoo! News
Immunomedics to Present at 51st ASH Annual Meeting
MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that nine pre...
GlobeNewswire via Yahoo! Finance,
Mon Nov 30 05:30:00 PST 2009
• Found on Yahoo! News
Celgene likey to see sales spike for its cancer pill Revlimid
Celgene can more than triple sales for its best-selling cancer pill Revlimid on new data that may persuade doctors to choose the drug as a first option over a Johnson & Johnson intravenous ...
The Star-Ledger,
Tue Dec 01 05:37:55 PST 2009
• Found on Yahoo! News
Celgene Cancer Pill to Triple Sales on Threat to J&J (Update2)
Nov. 30 (Bloomberg) -- Celgene Corp. can more than triple sales for its best-selling cancer pill Revlimid on new data that may convince doctors to choose the drug as a first option over Joh...
Bloomberg,
Mon Nov 30 13:44:11 PST 2009
• Found on Yahoo! News